Identification and analysis of CD133+ melanoma stem-like cells conferring resistance to taxol: An insight into the mechanisms of their resistance and response

Cancer Letters

Volumn 343, Issue 1, 2014, Pages 123-133

  El Khattouti, Abdelouahid ^a   Selimovic, Denis ^b   Haïkel, Youssef ^b   Megahed, Mosaad ^c   Gomez, Christian R ^a   Hassan, Mohamed ^a,b  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Apoptosis; Cancer stem cells; CD133; JNK; P38; Taxol

Indexed keywords

APOPTOSIS SIGNAL REGULATING KINASE 1; CASPASE 3; CASPASE 9; CD133 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PACLITAXEL; PROTEIN BAX;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CANCER STEM CELL; CD133+ CELL; CELL PROLIFERATION; CELL RENEWAL; CELL SUBPOPULATION; CONCENTRATION RESPONSE; DRUG CYTOTOXICITY; DRUG EFFICACY; HUMAN; HUMAN CELL; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION;

EID: 84890860169     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.09.024     Document Type: Article

References (39)

1. Chin L., Garraway L.A., Fisher D.E. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev. 2006, 20:2149-2182.
2. Helmbach H., Sinha P., Schadendorf D. Human melanoma: drug resistance. Recent Results Cancer Res. 2003, 161:93-110.
3. Li Y., Mcclay E.F. Systemic chemotherapy for the treatment of metastatic melanoma. Semin. Oncol. 2002, 29:413-426.
4. Soengas M.S., Lowe S.W. Apoptosis and melanoma chemoresistance. Oncogene 2003, 22:3138-3151.
5. Beddingfield F.C. The melanoma epidemic: res ipsa loquitur. Oncologist 2003, 8:459-465.
6. Thompson J.F., Scolyer R.A., Kefford R.F. Cutaneous melanoma. Lancet 2005, 365:687-701.
7. Jemal A., Devesa S.S., Hartge P., Tucker M.A. Recent trends in cutaneous melanoma incidence among whites in the United States. J. Natl. Cancer Inst. 2001, 93:678-683.
8. Breslow A. The surgical treatment of stage I cutaneous melanoma. Cancer Treat. Rev. 1978, 5:195-198.
9. Balch C.M., Soong S.J., Gershenwald J.E., Thompson J.F., Reintgen D.S., Cascinelli N., et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint committee on Cancer melanoma staging system. J. Clin. Oncol. 2001, 19:3622-3634.
10. Fang D., Nguyen T.K., Leishear K., Finko R., Kulp A.N., Hotz S., et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 2005, 65:9328-9337.
11. Frank N.Y., Margaryan A., Huang Y., Schatton T., Waaga-Gasser A.M., Gasser M., et al. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res. 2005, 65:4320-4333.
12. Grichnik J.M., Burch J.A., Schulteis R.D., Shan S., Liu J., Darrow T.L., et al. Melanoma, a tumor based on a mutant stem cell?. J. Invest. Dermatol. 2006, 126:142-153.
13. Monzani E., Facchetti F., Galmozzi E., Corsini E., Benetti A., Cavazzin C., et al. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur. J. Cancer 2007, 43:935-946.
14. Topczewska J.M., Postovit L.M., Margaryan N.V., Sam A., Hess A.R., Wheaton W.W., et al. Embryonic and tumorigenic pathways converge via nodal signaling: role in melanoma aggressiveness. Nat. Med. 2007, 12:925-932.
15. Wang E., Voiculescu S., Le Poole I.C., El-Gamil M., Li X., Sabatino M., et al. Clonal persistence and evolution during a decade of recurrent melanoma. J. Invest. Dermatol. 2006, 126:1372-1377.
16. Hendrix M.J., Seftor E.A., Hess A.R., Seftor R.E. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat. Rev. Cancer 2003, 3:411-421.
17. Bittner M., Meltzer P., Chen Y., Jiang Y., Seftor E., Hendrix M., et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000, 406:536-540.
18. Simpson A.J., Caballero O.L., Jungbluth A., Chen Y.T., Old L.J. Cancer/testis antigens, gametogenesis and cancer. Nat. Rev. Cancer 2005, 5:615-625.
19. Rothhammer T., Bataille F., Spruss T., Eissner G., Bosserhoff A.K. Functional implication of BMP4 expression on angiogenesis in malignant melanoma. Oncogene 2007, 26:4158-4170.
20. Balint K., Xiao M., Pinnix C.C., Soma A., Veres I., Juhasz I., et al. Activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma progression. J. Clin. Invest. 2005, 115:3166-3176.
21. Weeraratna A.T., Jiang Y., Hostetter G., Rosenblatt K., Duray P., Bittner M., et al. Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 2002, 1:279-288.
22. Klein W.M., Wu B.P., Zhao S., Wu H., Klein-Szanto A.J., Tahan S.R. Increased expression of stem cell markers in malignant melanoma. Mod. Pathol. 2007, 20:102-107.
23. Van Kempen L.C., Van Den Oord J.J., Van Muijen G.N., Weidle U.H., Bloemers H.P., Swart G.W. Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin. Am. J. Pathol. 2000, 156:769-774.
24. Hassan M., Mirmohammadsadegh A., Selimovic D., Nambiar S., Tannapfel A., Hengge U.R. Identification of functional genes during Fas-mediated apoptosis using a randomly fragmented cDNA library. Cell. Mol. Life Sci. 2005, 62:2015-2026.
25. Hassan M., Feyen O., Grinstein E. Fas-induced apoptosis of renal cell carcinoma is mediated by apoptosis signal-regulating kinase 1 via mitochondrial damage-dependent caspase-8 activation. Cell. Oncol. 2009, 31:437-456.
26. Hassan M., Selimovic D., Ghozlan H., Abdelkader O. Induction of high-molecular-weight (HMW) tumor necrosis factor (TNF) alpha by hepatitis C virus (HCV) non-structural protein 3 (NS3) in liver cells is AP-1 and NF-kappaB-dependent activation. Cell. Signal. 2007, 19:301-311.
27. Hassan M., Selimovic D., Ghozlan H., Abdelkader O. Hepatitis C virus core protein triggers hepatic angiogenesis by a mechanism including multiple pathways. Hepatology 2009, 49:1469-1482.
28. Hassan M., Ghozlan H., Abdelkader O. Activation of c-Jun NH2-terminal kinase (JNK) signaling pathway is essential for the stimulation of hepatitis C virus (HCV) non-structural protein 3 (NS3)-mediated cell growth. Virology 2005, 333:324-336.
29. Hassan M., Ghozlan H., Abdelkader O. Activation of RB/E2F signaling pathway is required for the modulation of hepatitis C virus core protein-induced cell growth in liver and non-liver cells. Cell. Signal. 2004, 16:1375-1385.
30. Sasaki A., Kamiyama T T., Yokoo H., Nakanishi K., Kubota K., Haga H., et al. Cytoplasmic expression of CD133 is an important risk factor for overall survival in hepatocellular carcinoma. Oncol. Rep. 2010, 24:537-546.
31. Nichols J., Zevnik B., Anastassiadis K., Niwa H., Klewe-Nebenius D., Chambers I., et al. Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. Cell 1998, 95:379-391.
32. Zangrossi S., Marabese M., Broggini M., Giordano R., D'Erasmo M., Montelatici E., et al. Oct-4 expression in adult human differentiated cells challenges its role as a pure stem cell marker. Stemm cells. 2007, 25:1675-1680.
33. Klein W.M., Wu B.P., Zhao S., Wu H., Klein-Szanto A.J., Tahan S.R. Increased expression of stem cell markers in malignant melanoma. Mod. Pathol. 2007, 20:102-107.
34. Swart G.W., Lunter P.C., Kilsdonk J.W., Kempen L.C. Activated leukocyte cell adhesion molecule (ALCAM/CD166): signaling at the divide of melanoma cell clustering and cell migration?. Cancer Metast. Rev. 2005, 24:223-236.
35. Jordan M.A., Wendell K., Gardiner S., Derry W.B., Copp H., Wilson L. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res. 1996, 56:816-825.
36. Liu G., Yuan X., Zeng Z., Tunici P., Ng H., Abdulkadir I.R., et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer 2006, 5:67.
37. Van der Jeught M., O'Leary T., Ghimire S., Lierman S., Duggal G., Versieren K., et al. The combination of inhibitors of FGF/MEK/Erk and GSK3β signaling increases the number of OCT3/4- and NANOG-positive cells in the human inner cell mass, But Does not improve stem cell derivation. Stem Cells Dev. 2013, 22:296-306.
38. Clarke M.F., Dick J.E., Dirks P.B., Eaves C.J., Jamieson C.H., Jones D.L., et al. Cancer stem cells-perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res. 2006, 66:9339-9344.
39. Gillet J.P., Calcagno A.M., Varma S., Davidson B., Bunkholt Elstrand M., Ganapathi R., et al. Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma. Clin. Cancer Res. 2012, 18:3197-3206.